[go: up one dir, main page]

PE20050078A1 - Derivados de pirrolidona como inhibidores de maob - Google Patents

Derivados de pirrolidona como inhibidores de maob

Info

Publication number
PE20050078A1
PE20050078A1 PE2003000956A PE2003000956A PE20050078A1 PE 20050078 A1 PE20050078 A1 PE 20050078A1 PE 2003000956 A PE2003000956 A PE 2003000956A PE 2003000956 A PE2003000956 A PE 2003000956A PE 20050078 A1 PE20050078 A1 PE 20050078A1
Authority
PE
Peru
Prior art keywords
phenyl
pyrrolidine
oxo
carboxyl
halogen
Prior art date
Application number
PE2003000956A
Other languages
English (en)
Inventor
Wolfgang Wostl
Synese Jolidon
Sarmiento Rosa Maria Rodriguez
Andrew William Thomas
Beat Wirz
Daniela Krummenacher
Hans Iding
Rene Wyler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20050078A1 publication Critical patent/PE20050078A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

REFERIDA A UN COMPUESTO DE FORMULA I, DONDE 1 ES =N-, =C(R24)-; X-Y ES -CH2-CH2-, -CH=CH-, -CH2-O-; R1, R1.1 Y R1.2 SON CADA UNO H, HALOGENO, CIANO, ENTRE OTROS; R21, R22 Y R23 SON CADA UNO H, HALOGENO; R24 ES H, HALOGENO, METILO; R3 ES -C(O)N(H)CH3, -CH2CN; R4 ES H. TAMBIEN REFERIDA A PROCESOS PARA SU PREPARACION DONDE SON COMPUESTOS PREFERIDOS: METILAMIDA DEL ACIDO (RS)-5-OXO-1-[4-(2,3,4-TRIFLUORO-BENCILOXI)-FENIL]-PIRROLIDINA-3-CARBOXILICO; METILAMIDA DEL ACIDO (RS)-1-[4-(3-FLUORO-BENCILOXI)-FENIL]- 5-OXO-PIRROLIDINA-3-CARBOXILICO Y METILAMIDA DEL ACIDO (RS)-(E)-1-{4-[2-(3-FLUORO-FENIL)-VINIL]-FENIL}-5-OXO-PIRROLIDINA-3-CARBOXILICO; ENTRE OTROS. DICHOS COMPUESTOS SON UTILES EN LA PREPARACION Y TRATAMIENTO DE ENFERMEDADES MEDIADAS POR INHIBIDORES DE MONOAMINO OXIDASA B COMO LA DE ALZHEIMER O DEMENCIA SENIL, ENTRE OTRAS
PE2003000956A 2002-09-20 2003-09-18 Derivados de pirrolidona como inhibidores de maob PE20050078A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02021319 2002-09-20

Publications (1)

Publication Number Publication Date
PE20050078A1 true PE20050078A1 (es) 2005-02-28

Family

ID=32010924

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2003000952A PE20050077A1 (es) 2002-09-20 2003-09-17 Derivados de 4-pirrolidino-fenil-bencil-eter
PE2003000956A PE20050078A1 (es) 2002-09-20 2003-09-18 Derivados de pirrolidona como inhibidores de maob
PE2003000958A PE20050079A1 (es) 2002-09-20 2003-09-18 Derivados de pirrolidona como inhibidores de maob

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2003000952A PE20050077A1 (es) 2002-09-20 2003-09-17 Derivados de 4-pirrolidino-fenil-bencil-eter

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2003000958A PE20050079A1 (es) 2002-09-20 2003-09-18 Derivados de pirrolidona como inhibidores de maob

Country Status (31)

Country Link
US (4) US7235581B2 (es)
EP (3) EP1542971A1 (es)
JP (3) JP4335142B2 (es)
KR (3) KR100676015B1 (es)
CN (3) CN100400509C (es)
AR (3) AR041297A1 (es)
AT (2) ATE472530T1 (es)
AU (3) AU2003273901B2 (es)
BR (4) BR0314314A (es)
CA (3) CA2498785C (es)
CY (1) CY1110745T1 (es)
DE (2) DE60331559D1 (es)
DK (1) DK1542970T3 (es)
ES (2) ES2344557T3 (es)
GT (3) GT200300205A (es)
HR (3) HRP20050261A2 (es)
JO (2) JO2605B1 (es)
MX (3) MXPA05002880A (es)
MY (3) MY134480A (es)
NO (3) NO329754B1 (es)
NZ (3) NZ538048A (es)
PA (3) PA8583001A1 (es)
PE (3) PE20050077A1 (es)
PL (3) PL216030B1 (es)
PT (1) PT1542970E (es)
RU (3) RU2323209C2 (es)
SI (1) SI1542970T1 (es)
TW (3) TWI286132B (es)
UY (3) UY27990A1 (es)
WO (3) WO2004026825A1 (es)
ZA (3) ZA200501137B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI286132B (en) * 2002-09-20 2007-09-01 Hoffmann La Roche 4-pyrrolidino-phenyl-benzyl ether derivatives
GB0314373D0 (en) 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
KR100845366B1 (ko) * 2004-08-02 2008-07-09 에프. 호프만-라 로슈 아게 모노아민 산화효소 ｂ 억제제로서 벤질옥시 유도체
US7456210B2 (en) * 2004-08-02 2008-11-25 Hoffmann-La Roche Inc. Benzyloxy derivatives
BRPI0606187A2 (pt) 2005-02-25 2009-06-09 Hoffmann La Roche comprimidos com capacidade de dispersão da substáncia do fármaco melhorada
BRPI0608466A2 (pt) * 2005-03-15 2010-01-05 Hoffmann La Roche método de preparação de derivados de éter 4-pirrolidinofenil benzìlico enantiomericamente puros
US7501528B2 (en) * 2005-03-15 2009-03-10 Hoffmann-La Roche Inc. Method for preparing enantiomerically pure 4-pyrrolidino phenylbenzyl ether derivatives
TW200728258A (en) 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
DE602006015215D1 (de) * 2005-10-10 2010-08-12 Glaxo Group Ltd Prolinamidderivate als natriumkanalmodulatoren
TW200730494A (en) 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
CA2706017A1 (en) * 2007-03-30 2008-10-09 Jorge R. Barrio In vivo imaging of sulfotransferases
KR101220182B1 (ko) * 2009-02-25 2013-01-11 에스케이바이오팜 주식회사 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법
CZ304053B6 (cs) * 2011-08-22 2013-09-04 Farmak, A. S. Zpusob prípravy 2-[4-[(methylamino)karbonyl]-1-H-pyrazol-1-yl]adenosinu monohydrátu
KR102018284B1 (ko) * 2013-02-28 2019-09-05 삼성디스플레이 주식회사 박막 트랜지스터 어레이 기판 및 이를 포함하는 유기 발광 표시 장치
AU2014241759B2 (en) 2013-03-14 2017-10-19 Dart Neuroscience (Cayman) Ltd. Substituted naphthyridine and quinoline compounds as MAO inhibitors
CZ305213B6 (cs) * 2013-04-29 2015-06-10 Farmak, A. S. Polymorf E 2-[4-[(methylamino)karbonyl]-1H-pyrazol-1-yl]adenosinu a způsob jeho přípravy
RU2016118748A (ru) 2013-10-29 2017-12-05 Ф. Хоффманн-Ля Рош Аг Кристаллические формы производного пирролидона, полезные при лечении болезни альцгеймера, и их получение
ES2912881T3 (es) 2014-12-23 2022-05-30 Convergence Pharmaceuticals Procedimiento para preparar derivados de alfa-carboxamida pirrolidina
WO2016156124A1 (en) 2015-03-27 2016-10-06 F. Hoffmann-La Roche Ag Pharmaceutical formulation comprising sembragiline
WO2019065794A1 (ja) 2017-09-27 2019-04-04 国立大学法人鹿児島大学 Ｐａｃ１受容体拮抗薬を用いた鎮痛薬
CA3076823A1 (en) 2017-10-05 2019-04-11 Biogen Inc. Process for preparing alpha-carboxamide pyrrolidine derivatives
CN108299272B (zh) * 2018-01-31 2019-10-18 福州大学 一种合成1-氯-2,2,2-三氟亚乙基取代咯酮化合物的方法
EP3762364B1 (en) * 2018-03-08 2023-08-23 Sunshine Lake Pharma Co., Ltd. Pyrrolidineamide derivatives and uses thereof
EP3932490B1 (en) 2019-02-27 2025-04-02 Kagoshima University Antipruritic agent using pac1 receptor antagonist
WO2021225161A1 (ja) 2020-05-08 2021-11-11 国立大学法人鹿児島大学 Ｐａｃ１受容体拮抗薬を用いた抗うつ・抗不安薬
CN112851561A (zh) * 2021-01-29 2021-05-28 南京艾美斐生物医药科技有限公司 一种nr6a1蛋白受体抑制剂及其制备和应用
WO2022268520A1 (de) 2021-06-21 2022-12-29 Bayer Aktiengesellschaft Verwendung von substituierten pyrrolidinonen oder deren salzen zur steigerung der stresstoleranz in pflanzen.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348393A (en) * 1978-06-09 1982-09-07 Delalande S.A. N-Aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones
FR2500831A1 (fr) * 1981-02-27 1982-09-03 Delalande Sa Nouvelles n-aryl-oxazolidinones et -pyrrolidinones
DE69025418T2 (de) 1989-04-19 1996-11-14 Otsuka Pharma Co Ltd Phenylcarbonsäurederivate mit einem Heterocyclus
ATE253057T1 (de) * 1994-08-30 2003-11-15 Sankyo Co Isoxazole
US5679715A (en) 1995-06-07 1997-10-21 Harris; Richard Y. Method for treating multiple sclerosis
WO1997033572A1 (en) 1996-03-15 1997-09-18 Somerset Pharmaceuticals, Inc. Method for preventing and treating peripheral neurophathy by administering selegiline
US5683404A (en) * 1996-06-05 1997-11-04 Metagen, Llc Clamp and method for its use
DE19841895A1 (de) 1998-09-11 2000-03-23 Degussa Neues Verfahren zur Herstellung von 3-Amino-2-oxo-pyrrolidinen, neue Zwischenprodukte und deren Verwendung
EP1165546A2 (en) * 1999-04-02 2002-01-02 Du Pont Pharmaceuticals Company Novel lactam inhibitors of matrix metalloproteinases, tnf-alpha, and aggrecanase
WO2001034172A2 (en) 1999-11-05 2001-05-17 Vela Pharmaceuticals Inc. Methods and compositions for treating reward deficiency syndrome
CA2398496C (en) * 2000-02-10 2009-05-19 Surgical Development Ag Urinary incontinence treatment with wireless energy supply
WO2001047441A2 (en) * 2000-02-14 2001-07-05 Potencia Medical Ag Penile prosthesis
TWI286132B (en) * 2002-09-20 2007-09-01 Hoffmann La Roche 4-pyrrolidino-phenyl-benzyl ether derivatives
US20040267291A1 (en) * 2003-06-27 2004-12-30 Byrum Randal T. Implantable band with non-mechanical attachment mechanism
US20040267292A1 (en) * 2003-06-27 2004-12-30 Byrum Randal T. Implantable band with transverse attachment mechanism

Also Published As

Publication number Publication date
HK1083499A1 (zh) 2006-07-07
RU2005111968A (ru) 2006-11-10
NO20050665L (no) 2005-04-18
JP4335140B2 (ja) 2009-09-30
TW200408624A (en) 2004-06-01
US7037935B2 (en) 2006-05-02
AU2003270213B8 (en) 2009-03-05
HK1084383A1 (en) 2006-07-28
AU2003270213B2 (en) 2009-02-12
HRP20050263A2 (en) 2006-12-31
JP2006503834A (ja) 2006-02-02
MXPA05002878A (es) 2005-05-27
WO2004026827A1 (en) 2004-04-01
BR0314631A (pt) 2005-08-02
AU2003270213A1 (en) 2004-04-08
WO2004026826A1 (en) 2004-04-01
CA2498785C (en) 2011-07-26
SI1542970T1 (sl) 2010-08-31
TWI331994B (en) 2010-10-21
AU2003273901B2 (en) 2008-07-10
RU2005111969A (ru) 2006-01-20
CN100503562C (zh) 2009-06-24
CA2496756C (en) 2012-01-10
ZA200501137B (en) 2006-12-27
AR041298A1 (es) 2005-05-11
CN100383118C (zh) 2008-04-23
MY135696A (en) 2008-06-30
DE60333202D1 (de) 2010-08-12
TW200413350A (en) 2004-08-01
JO2605B1 (en) 2011-11-01
MXPA05002881A (es) 2005-05-27
PL216030B1 (pl) 2014-02-28
US20040097578A1 (en) 2004-05-20
NZ538048A (en) 2007-05-31
EP1542969A1 (en) 2005-06-22
UY27990A1 (es) 2004-03-31
PA8583601A1 (es) 2004-09-16
BR0314299A (pt) 2005-12-13
KR20050057456A (ko) 2005-06-16
MY133332A (en) 2007-11-30
NO20050652L (no) 2005-03-08
MXPA05002880A (es) 2005-05-27
EP1542971A1 (en) 2005-06-22
AU2003273901A1 (en) 2004-04-08
ATE459601T1 (de) 2010-03-15
EP1542969B1 (en) 2010-03-03
EP1542970A1 (en) 2005-06-22
CN1681779A (zh) 2005-10-12
NZ538049A (en) 2007-05-31
PT1542970E (pt) 2010-07-19
RU2336267C2 (ru) 2008-10-20
PL376021A1 (en) 2005-12-12
CY1110745T1 (el) 2015-06-10
NO329754B1 (no) 2010-12-13
AU2003267381A1 (en) 2004-04-08
JP2006510596A (ja) 2006-03-30
NZ538046A (en) 2007-08-31
MY134480A (en) 2007-12-31
US20060122235A1 (en) 2006-06-08
CN100400509C (zh) 2008-07-09
KR20050057450A (ko) 2005-06-16
KR20050057466A (ko) 2005-06-16
US20040106650A1 (en) 2004-06-03
CA2496756A1 (en) 2004-04-01
HK1083498A1 (zh) 2006-07-07
JP2006503833A (ja) 2006-02-02
NO20050701L (no) 2005-03-02
US20040116707A1 (en) 2004-06-17
ES2344557T3 (es) 2010-08-31
DK1542970T3 (da) 2010-08-02
ES2338646T3 (es) 2010-05-11
ZA200501311B (en) 2006-10-25
HRP20050261A2 (en) 2006-05-31
RU2005111974A (ru) 2006-01-20
HRP20050262A2 (en) 2006-06-30
AU2003267381B2 (en) 2009-08-27
BR0314314A (pt) 2005-07-26
UY27993A1 (es) 2004-03-31
TWI286132B (en) 2007-09-01
TWI337604B (en) 2011-02-21
US7151111B2 (en) 2006-12-19
JO2604B1 (en) 2011-11-01
CA2498785A1 (en) 2004-04-01
BRPI0314631B1 (pt) 2018-04-17
DE60331559D1 (de) 2010-04-15
NO330012B1 (no) 2011-02-07
TW200410935A (en) 2004-07-01
CN1681777A (zh) 2005-10-12
CN1681778A (zh) 2005-10-12
US7235581B2 (en) 2007-06-26
CA2498335A1 (en) 2004-04-01
KR100681586B1 (ko) 2007-02-09
PE20050079A1 (es) 2005-03-01
AR041297A1 (es) 2005-05-11
JP4335142B2 (ja) 2009-09-30
WO2004026825A1 (en) 2004-04-01
GT200300205A (es) 2004-04-29
KR100676015B1 (ko) 2007-01-30
ZA200501557B (en) 2005-09-08
JP4335141B2 (ja) 2009-09-30
UY27991A1 (es) 2004-03-31
PL376018A1 (en) 2005-12-12
PA8583001A1 (es) 2004-04-23
KR100676014B1 (ko) 2007-01-30
GT200300204A (es) 2004-04-29
EP1542970B1 (en) 2010-06-30
RU2336268C2 (ru) 2008-10-20
ATE472530T1 (de) 2010-07-15
PE20050077A1 (es) 2005-03-01
HRP20050263B1 (hr) 2013-09-30
RU2323209C2 (ru) 2008-04-27
PA8583501A1 (es) 2004-04-23
PL376019A1 (en) 2005-12-12
GT200300206A (es) 2004-04-29
AR041299A1 (es) 2005-05-11
US7122562B2 (en) 2006-10-17

Similar Documents

Publication Publication Date Title
PE20050078A1 (es) Derivados de pirrolidona como inhibidores de maob
ATE440087T1 (de) 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
NO20063928L (no) Substituerte kinolinforbindelser
ATE368656T1 (de) Piperidinderivate zur verwendung bei der behandlung von durch chemokins vermittelten leiden
NO20012158L (no) Substituerte 2-fenylbenzimidazoler, fremgangsmåte til fremstilling og anvendelse derav
BRPI0514865A (pt) processo para preparar um composto
NO20070368L (no) Virale polymeraseinhibitorer
PE20050018A1 (es) Compuesto pentaciclico heteroaromatico como inhibidor de la proteina tirosina fosfatasa 1b (ptb1b)
NO20062370L (no) Amidderivater
NO20056010L (no) Biaryloksymetylaren-karboksylsyrer
DE50011034D1 (de) N-substituierte 4-aminopteridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
PE20040667A1 (es) Derivados de cinamida
NO20074303L (no) 7-{4-[2-(2,6-diklor-4-metylfenoksy)etoksy]fenyl}-3,9-diazabisyklo-[3.3.1]non-6-en-6-karboksylsyresyklopropyl-(2,3-dimetylbenzyl)amid som renininhibitor til behandling av hypertensjon
ATE370131T1 (de) Verfahren zur herstellung von 5-(1,3-oxazol-2- yl)benzoesäurederivaten
PE20040594A1 (es) Derivados de isoquinolina
ATE347550T1 (de) Polymorph von 4-(2-(4-(1-(2-ethoxyethyl)-1h- benzimidazol-2-yl)-1-piperidinyl)ethyl)-alpha, alpha-dimethylbenzolessigsäure
BR0312586A (pt) Derivados de pirolidina como antagonistas e oxitocina
NO20070972L (no) Benzyloksyderivater som MAOB-inhibitorer
DE60310609D1 (de) Verfahren zur herstellung von 2-aminomethylpyridin-derivaten
DE602006009556D1 (de) Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen
ATE546432T1 (de) Verfahren zur herstellung von 2- aminomethylpyridin-derivate
RU2004126953A (ru) Производное пиперидина и фармацевтическая композиция, включающая его в качестве активного ингредиента
DK1968957T3 (da) Substituerede thiazoler og anvendelse deraf til fremstilling af lægemidler
BRPI0408148A (pt) derivados de ácido benzoilureidopiridil-piperidina e -pirrolidina-carboxìlico, processos para a preparação e uso dos mesmos
DK1214315T3 (da) 1,4-Dihydropyridin-5-carboxylsyreesterderivater og fremgangsmåde til fremstilling af samme

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed